CTXR — Citius Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Citius Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Announces $3 Mln Registered Direct Offering
Brief: Citius Pharmaceuticals And Citius Oncology Highlight Lymphir Commercial Launch Planned For First Half Of 2025
Brief: Citius Pharmaceuticals Inc - Regains Compliance With Nasdaq Listing Rule 5550(A)(2)
Brief: Citius Pharmaceuticals Reports Productive FDA Type C Meeting
U.S. STOCKS ON THE MOVE-CC Holding, CBRE, Lexicon Pharmaceuticals
U.S. STOCKS ON THE MOVE-Jet.AI, SL Green, WTW
Citius Pharmaceuticals falls after announcement of reverse stock split
Brief: Citius Pharmaceuticals Announces 1-For-25 Reverse Stock Split
Brief: Citius Pharmaceuticals And Citius Oncology Announce Promising Preliminary Results Of An Investigator-Initiated Phase I Clinical Trial Of Pembrolizumab (KEYTRUDA) And LYMPHIR In Cancer Patients With Recurrent Solid Tumors
Brief: Citius Pharmaceuticals Says Dr Reddy's Agreed To Partial Deferral Without Penalty Of Milestone Payment By Citius Oncology
Citius Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Citius Pharmaceuticals Inc expected to post a loss of 6 cents a share - Earnings Preview
US FDA approves Citius' blood cancer therapy with boxed warning (updated)
US FDA approves Citius' blood cancer therapy
U.S. STOCKS ON THE MOVE-ProShares Ether, International Business Machines, Alvotech
U.S. STOCKS ON THE MOVE-Durect, Mangoceuticals, International Business Machines
U.S. STOCKS ON THE MOVE-Nikola, Citius Pharmaceuticals, Full Truck Alliance
Citius Pharma surges as anti-infective drug succeeds in late-stage study